Hematology/Oncology News

The European Medicines Agency Committee for Medicinal Products for Human Use has recommended the launch of proposed biosimilar rituximab candidate Ituxredi, Dr. Reddy’s Laboratories announced in a press release.

A prediction model could be a “starting point” to identify patients with metabolic dysfunction-associated steatotic liver disease at high risk for hepatocellular carcinoma who may require intervention or surveillance, researchers wrote.

The addition of an investigational immunotherapy to chemotherapy prolonged survival for women with advanced ovarian cancer, according to a topline data announcement.

Editor’s note: This is the fifth in a series of five stories from ASCO Voices, a session during ASCO Annual Meeting that focused on the human side of oncology.

An immunotherapy combination improved outcomes compared with historical control for certain patients with advanced melanoma, according to a topline data announcement.

Sociodemographic factors may contribute to disparities in testing for two key biomarkers among patients with metastatic colorectal cancer, according to study results.

Older adult cancer survivors who were overweight or obese at the time of first primary cancer diagnosis had a higher risk for developing second cancers, according to findings presented at ASCO Annual Meeting.

The FDA has approved Guardant Health’s Shield blood test to screen for colorectal cancer in patients aged 45 years and older at average risk for disease, according to a company press release.

Despite years of study and advances in breast cancer treatment, Otis Brawley, MD, professor of oncology at Johns Hopkins School of Medicine, said the disparity between the mortality rates of Black and white patients has never been greater.

Fixed-duration acalabrutinib plus venetoclax, with or without obinutuzumab, improved survival compared with standard chemoimmunotherapy for certain adults with leukemia, according to a topline data announcement.